Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind ( BLESS ) study
Psychiatry and Clinical Neurosciences · 2024-02 · 78 (2) · 113-122
DOI: 10.1111/pcn.13615 ↗At a glance
Randomisierte kontrollierte Studie in Psychiatry and Clinical Neurosciences, 2023-12. Written by Masaki Kato and 10 co-authors. Institution: Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan. Major MEDLINE topics: Major Depressive Disorder, Thiophenes, Quinolones. Cited 9 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical.
Abstract (original language)
Aims
Inadequate antidepressant response interrupts effective treatment of major depressive disorder (MDD). The BLESS study evaluates the dosage, efficacy, and safety of brexpiprazole adjunctive therapy in Japanese patients with inadequate antidepressant therapy (ADT) response.
Methods
This placebo‐controlled, randomized, multicenter, parallel‐group phase 2/3 study randomized Japanese MDD patients (Hamilton Rating Scale for Depression 17‐item total score ≥ 14; historical inadequate response to 1–3 ADTs) with inadequate response to 8‐week single‐blind, prospective SSRI/SNRI treatment to 6‐week adjunctive treatment with brexpiprazole 1 mg, 2 mg, or placebo. The primary endpoint was change in Montgomery‐Åsberg Depression Rating Scale (MADRS) total score from baseline. Secondary endpoints included MADRS response, remission rate, and Clinical Global Impression‐Improvement score. Safety was comprehensively evaluated, especially regarding antipsychotic adverse events (AEs).
Results
Of 1194 screened patients, 740 were randomized and 736 (1 mg, n = 248; 2 mg, n = 245; placebo, n = 243) had ≥1 baseline/post‐baseline MADRS total score. The LSM (SE) change from baseline in MADRS total score at Week 6 by MMRM analysis was −8.5 (0.47) with brexpiprazole 1 mg, −8.2 (0.47) with brexpiprazole 2 mg, and −6.7 (0.47) with placebo (placebo‐adjusted LSM difference [95% CI]: 1 mg, −1.7 [−3.0, −0.4]; P = 0.0089; 2 mg, −1.4 [−2.7, −0.1]; P = 0.0312). Secondary efficacy results supported the primary endpoint. Brexpiprazole was generally well tolerated.
Conclusion
Brexpiprazole 1 mg daily was an appropriate starting dose and both 1 mg and 2 mg daily were effective and well tolerated as adjunctive therapy for Japanese MDD patients not adequately responsive to ADT.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
- Clinical Development, Headquarters of Clinical Development Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan.
- Clinical Development, Headquarters of Clinical Development Otsuka Pharmaceutical Co. Ltd., Osaka, Japan.
- Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
- Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
- Japan Depression Center, Tokyo, Japan.
ORCID profiles: Masaki Kato, Yuki Isogai
Funding
- Otsuka Pharmaceutical Co., Ltd.
- Otsuka Pharmaceutical
Cite
APA
Kato, M., Shiosakai, M., Kuwahara, K., Iba, K., Shimada, Y., Saito, M., Isogai, Y., Sekine, D., Aoki, K., Koga, N., & Higuchi, T. (2024). Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind ( BLESS ) study. Psychiatry and Clinical Neurosciences, 78(2), 113-122. https://doi.org/10.1111/pcn.13615
Vancouver
Kato M, Shiosakai M, Kuwahara K, Iba K, Shimada Y, Saito M, et al. Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind ( BLESS ) study. Psychiatry and Clinical Neurosciences. 2024;78(2):113-122. doi:10.1111/pcn.13615
BibTeX
@article{Kato2024,
author = {Kato, Masaki and Shiosakai, Masako and Kuwahara, Kazuo and Iba, Katsuhiro and Shimada, Yuki and Saito, Mizuki and Isogai, Yuki and Sekine, Daisuke and Aoki, Kazuo and Koga, Nobuyuki and Higuchi, Teruhiko},
title = {Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind ( BLESS ) study},
journal = {Psychiatry and Clinical Neurosciences},
year = {2024},
volume = {78},
number = {2},
pages = {113--122},
doi = {10.1111/pcn.13615}
}
EUVIMED